WANY
LAB icon

Wealthspire Advisors (New York)’s Standard BioTools LAB Stock Holding History

Wealthspire Advisors (New York)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$260 – 2043
2025
Q3 		$260 Buy
+200
New +$262 ﹤0.01% 2911

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Wealthspire Advisors (New York)'s LAB Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Standard BioTools (LAB) in Q4 2025, closing a stake of 200 shares — an estimated $260 sold.

Wealthspire Advisors (New York) first reported a position in LAB in Q3 2025 and held it in 1 quarter. The position peaked at $260 in Q3 2025. 159 funds tracked by Wall St. Rank hold LAB as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Standard BioTools position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 200 Standard BioTools shares in Q4 2025, an estimated $260.
  • Wealthspire Advisors (New York) first reported a position in Standard BioTools in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Standard BioTools position peaked at $260 in Q3 2025.
  • 159 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.